Regent Capital
VC Fund
Shenzhen, China
Regent Capital is an investment firm to provide both equity and debt financing for middle-market companies or projects. The capital they provide is primarily used for opportunities which are not satisfied by the straight equity investment or conventional bank lending. They invest mainly in Asia, with a particular focus on China.Their investmentstrategy emphasizes on identifying industry or sector trends and themes, and then carefully assessing opportunities arising from these themes in connection with potential investments. This strategy of thesis-based investing is distinctive, in many respects, from other firms in the industry. Their team are sector experts with deep knowledge on several industries, such as real estate, utilities, infrastructure and consumer products. They mainly rely on their proprietary network to identify investment opportunities.Regent Capital expects to be the lead investor with a significant majority of their portfolio investments, and to be in an influential position to help their portfolio companies to better understand the industrial landscape, improve the operating efficiency and manage its capital structure.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Regent Capital invests in
Stages Regent Capital invests in
Countries Regent Capital invests in
Investment Focus
Industry
- Health Care 2 (40%)
- Therapeutics 2 (40%)
- Biotechnology 2 (40%)
- Finance 1 (20%)
- Lending 1 (20%)
Stage
- Series B 3 (60%)
- Series A 1 (20%)
Country
- China 3 (60%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ITabMed
|
ITabMed is a clinical-stage biotech company located in Shanghai, China. The company was founded in 2020 and is registered in Lin Gang Sci-Tech City, Shanghai. It was a spin-off entity from the former “Generon BioMed Ltd.”. The company is focused on immunotherapy drug research and development to treat cancer. | $20M / Series A / Dec 01, 2021 | |
Goldfinch Biopharma
|
Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease. It is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Its Product Engine willindustrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. The company was founded in 2016 and is based in Cambridge, Massachusetts. | $100M / Series B / Jun 30, 2020 | |
Danke Apartment
|
Danke Apartment (蛋壳公寓) is a leading internet enabled apartment management startup in China. Founded in Jan 2015, Danke is managing over 320K apartment units in Beijing, Shanghai, Shenzhen, Hangzhou, etc | $70M / Series B / Jun 06, 2018 | |
|
Danke Apartment
|
Danke Apartment (蛋壳公寓) is a leading internet enabled apartment management startup in China. Founded in Jan 2015, Danke is managing over 320K apartment units in Beijing, Shanghai, Shenzhen, Hangzhou, etc | $100M / Series B / Feb 26, 2018 | |
Chedai.com
|
The first car loan by CITIC Group, Beijing Automotive Group, Matrix Partners, and Brilliance China joint venture China's first credit auto finance O2O service platform. Team consists of professionals from the automotive, financial, Internet, three major areas of composition, dedicated to the automobile industry chain links in new car dealers,used car dealers, car rental business, automotive parts suppliers, vehicle logistics providers, automotive consumers provide tailor-made financial solutions. | Series B / Jan 06, 2017 |
Co-Investors
Gaorong Capital
2 deals together
BAI capital
2 deals together
CMC Capital Group
2 deals together
Eventide
2 deals together
Irving Investors
2 deals together
Joy Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Regent Capital invest in?
Regent Capital invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Regent Capital last invest?
The most recent investment recorded for Regent Capital closed in Dec 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
